摘要
背景与目的:用杂交瘤技术制备脐血树突状细胞(DC)和食管癌细胞的融合瘤苗,探讨其在体内诱导抗肿瘤效应。材料与方法:分离脐血CD34+干细胞诱导扩增为成熟DC,与EC109细胞经聚乙二醇(PEG)法融合;免疫磁珠法筛选EC109-DC,鉴定瘤苗表型和致瘤性;观察该瘤苗的体内成瘤性、保护性免疫反应和免疫治疗效果。结果:融合瘤苗可体外生长,并高表达CD80、CD83、CD86和叶酸受体(FR);瘤苗接种小鼠体内未见肿瘤形成;经瘤苗免疫的小鼠,肿瘤生长的潜伏期较对照组明显延长(P<0.05),肿瘤的大小和肿瘤重量均明显小于对照组(P<0.05)。用融合瘤苗治疗的荷瘤小鼠,肿瘤的大小和重量也均明显小于对照组(P<0.05)。结论:融合瘤苗EC109-DC同时表达EC109和DC特异性抗原,无体内致瘤性,对EC109细胞的攻击有明显的抵抗作用,对治疗荷瘤小鼠有一定的作用。
BACKGROUND ＆ AIM： To prepare a fusion vaccine with esophageal carcinoma cell （EC109）and dendritic cells（DC）, and to study the protective and therapeutic effects against EC109 cells. MATERIALS AND METHODS： Fusion vaccine of EC109-DC（ED） was produced by traditional PEG fusing, cytokine inducing, CD34^＋ magnetic microbead marker sorting, and MACS（magnetic cell sorting system） The therapeutic and protective effects of the fusion vaccine against tumor EC109 were analyzed by flow cytometry, RESULTS： The fusion cells ED expressed high levels of FR（folate receptor）, CD80, CD83 and CD86. No tumor was found in the spleen, lung and liver of mice after the injection of fusion vaccine ED. In the immuned group, latent period was longer in ED subgroup than in others, and tumor size and tumor weight were also less than those in ED subgroup. In the therapeutic group, tumor size and tumor weight were less in ED subgroup than in control（PBS group）, inactivated EC109 and DC group. CONCLUSION： The fusion cells EC109-DC expressed specific antigens. The fusion vaccine didn＇t have oncogenetic effects in vivo, but demonstrated immunologic protection against tumor EC109 and certain effect on inhibiting tumor growth in mice.
出处
《癌变．畸变．突变》
CAS
CSCD
2007年第1期11-14,共4页
Carcinogenesis,Teratogenesis & Mutagenesis
基金
广东省自然科学基金项目(No021228)
关键词
树突状细胞
食管癌细胞
细胞融合
免疫保护
免疫治疗
dendritic cells
esophageal carcinoma cell
cell fusion
immunologic protection
immunotherapy
